UPDATE 1-Infection worries prompt regulatory reviews of Gilead leukaemia drug
 

UPDATE 1-Infection worries prompt regulatory reviews of Gilead leukaemia drug
LONDON, March 11 (Reuters) - European and U.S. regulators are reviewing the safety of Gilead Sciences' leukaemia drug Zydelig due to concerns over serious adverse events, including deaths.
http://i0.wp.com/reuters.us.feedspor...f?resize=1%2C1http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...ag:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...ag:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/13pq6bP5l3M